Paclitaxol and cisplatin combination in second-line treatment of recurrent small cell lung cancer

Objective To investigate the activity and toxicity of paclitaxol plus cisplatin in secondline treatment of small cell lung cancer.Methods Thirty-eight patients were enrolled and received paclitaxol 135 mg/m2 d1,cisplatin 70 mg/m2 d1-3.All treatment was delivered every three or four weeks.Results One patient was failing to complete the treatment by the side effects.Thirty-seven patients were valuable for response.Twelve partial responses were observed,overall response rate was 31.6 ％,control rate of disease was 68.4％,and the median duration was 6.8 months.Thirty-eight patients were evaluating for toxicity.WHO grade Ⅲ leucopoenia,neutrogena occurred in 47.4％,57.9％,grade Ⅳ neutropenia in 15.8％ cases.WHO grade Ⅲ fatigue and vomit occurred in 55.3％,31.6％.Conclusions Combination of paclitaxol plus cisplatin is effective and tolerate in small cell lung cancer patients. Key words: Paclitaxol;  Small cell lung cancer;  Retreatment ; Combined chemotherapy